Alvotech declared that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s planned biosimilar to Eylea® (aflibercept).

CV6 Therapeutics has reported the successful administration of the second patient in its Phase 1a clinical trial assessing CV6-168 in combination with infusional 5-fluorouracil (5-FU) for cancer treatment.

UroGen Submits NDA for UGN-102, Aiming for FDA Approval as the First Treatment for Intermediate-Risk, Low-Grade Non-Muscle Invasive Bladder Cancer.

Verrica Pharmaceuticals Reveals Encouraging Initial Topline Data from Phase 2 Study Part 2 of VP-315, an Experimental Oncolytic Peptide Immunotherapy for Basal Cell Carcinoma Treatment.

ACELYRIN revealed that the Phase 3 trial of izokibep for Hidradenitis Suppurativa (HS) successfully met its primary endpoint of HiSCR75 at the 12-week mark.

Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. FDA has accepted and given Priority Review status to the Biologics License Application (BLA) for CHIKV VLP(PXVX-0317).

Galderma has revealed that the U.S. FDA has given the green light to Nemluvio® (nemolizumab) as a pre-filled pen designed for subcutaneous injection to treat adults suffering from prurigo nodularis.1.

Biosyngen is excited to share that the U.S. Food and Drug Administration (FDA) has given the green light for its BRG01, an EBV-specific CAR-T cell therapy.

VISEN Pharmaceuticals reported that the Phase 3 PaTHway China Trial of Palopegteriparatide met its main and key secondary goals in treating adults with hypoparathyroidism.

Kyverna Therapeutics' KYV-101 Granted RMAT Designation by FDA for Progressive Myasthenia Gravis Treatment.

Initial Patient Administered in Phase 2 Study of New Anti-TIGIT Fc Fusion Protein with Serplulimab and HANBEITAI for First-line Therapy in Advanced Hepatocellular Carcinoma.

This research is assessing the administration of two doses of the ABRYSVO vaccine in immunocompromised adults aged 18.